News
News / Press Releases
Astellas Announces Reimbursement for XTANDI® (enzalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Read More about this newsThis website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.
Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.